ACER.OOTC
- Acer Therapeutics
報價延遲最少15分鐘:2024/05/03 05:57 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
-- 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.93/0.75
|
|
企業價值
16.15M
|
| 資產負債 |
|
每股賬面淨值
-1.36
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
--
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||
|
||||||||||||||||
報價延遲最少15分鐘：2024/05/03 05:57 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Acer Therapeutics Inc operates as a pharmaceutical company. Principally, it is focused on the acquisition, development, and commercialization of therapies for patients with serious rare and ultra-rare diseases with a critical unmet medicalneed. The company's clinical pipeline includes three categories of severe genetic disorders namely EDSIVO for vEDS, and ACER-001 for urea cycle disorders and maple syrup urine disease. |